Citations

Clear

76 citation(s) found for "Barnard, J".

A107-05 Pseudogene Transcripts Associated With Pulmonary Hypertension Identified in the RNA Sequencing Study From the PVDOMICS Cohort
Grunig, G, Kim, R, Kwon, S, Berman-Rosenzweig, E, Horn, E M, Leopold, J A, Hassoun, P M, Mathai, S C, Simpson, C, Mehra, R, Aldred, M, Frantz, R P, Rischard, F P, Hemnes, A R, Beck, G J, Hill, N S, Erzurum, S C, Comhair, S A, Barnard, J, Mathai, Stephen C. , Mathai, Stephen C , Grünig, Gabriele , Rosenzweig, Erika B. , Leopold, Jane A. , Hassoun, Paul M. , Aldred, Micheala A. , Frantz, Robert P. , Rischard, Franz , Beck, G J, Comhair, S A, Barnard, J

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5618 Get It

Abstract Rationale Pulmonary hypertension (PH) is a heterogeneous condition classified into 5 WSPH groups but lacking detailed molecular distinction. The PVDOMICS cohort includes all PH groups alongside healthy and disease comparators, is deeply clinically phenotyped and has RNA sequencing data. Pseudogenes are conserved genome elements that due to sequence-defects cannot be translated into functional proteins. Some pseudogenes never-the-less produce RNA-transcripts which can regulate the expression of other, protein coding genes. Therefore, our study was focused on identifying differentially expressed pseudogene-transcripts within the dataset from the PVDOMICS study and gaining insights into their potential function. Methods Peripheral venous whole blood was collected from PVDOMICS participants [n = 525 PH patients; n = 312 controls without PH who were comparators (n = 256) or healthy (n = 56)]. RNA was isolated, RNA sequencing was performed. After quality control, differential transcript expression between PH and control groups was analyzed using the limma-voom pipeline, rSEA with adjustment for age, sex, race, smoking, WSPH group, latent factors and false discovery rate. We focused on a) transcripts expressed at increased levels (n = 218): the first 200 DEG (differentially-expressed-genes)-transcripts based on log2 difference plus increased DEG within the first 200 most significant p-values; and b) transcripts expressed at decreased levels (n = 292): last 200 DEG based on log2 difference plus decreased DEG within the first 200 most significant p-values. Results Six pseudogene transcripts were among the increased and 35 pseudogene transcripts were among the decreased DEG in the PH group compared to controls. Some of the differentially expressed pseudogenes (DEP) belonged to gene families, like the ribosomal protein family (7 DEP), mitochondria expressed transcripts (3 DEP), zinc finger proteins (2 DEP). Associations of pseudogenes with biological function or disease were extracted via GeneCards(R) and information from GWAS analysis. The DUSP8P5 pseudogene was among the DEP and is known for its association with left heart disease and hypertension; 2 additional DEP have known association with hypertension. Further known associations were with inhibitory or inflammatory immune processes (8 DEP), bone density (6 DEP), metabolism and diabetes (6 DEP), respiratory function or disease (4 DEP), erythrocyte biology (3 DEP), cancer (5 DEP), kidney disease (1 DEP), and demographic parameters like eye or hair color (2 DEP). Ten DEP had no known association with function or disease. Conclusions We identified pseudogene RNA-transcripts associated with PH across WSPH groups. The local vs. systemic effects of these pseudogene transcripts on PH remain to be determined and regulators of pseudogene-transcript expression (e.g. environmental exposures) identified. This abstract is funded by: 1 X01 HL148611 (TopMed), PVDOMICS NHLBI, PVDOMICS Pulmonary Hypertension Association, HT9425-25-1-0533 (GG), 1R21OH012955-01 (GG)
C101-06 Interactions of Leukotriene-B4 and Interleukin-8 Gene Variants and Protein Levels With PI*MZ Heterozygosity Among the COPDGene and SPIROMICS Cohorts
Tejwani, V, Bazeley, P, Barjaktarevic, I, Barnard, J, Bleecker, E R, Cho, M H, Curtis, J L, Moll, M, Meyers, D A, Ruvuna, L, Shrivastav, A, Siddharthan, T, Silverman, E K, Stoller, J K, Zhang, J, Bowler, R P, Zein, J G, Hersh, C P, Ortega, V E, Bazeley, Peter , Cho, Michael H. , Curtis, Jeffrey L. , Meyers, Deborah A. , Ruvuna, L. , Stoller, James K. , Zein, Joe , Hersh, Craig P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2025 Get It

Abstract Rationale Deficiency of alpha-1 antitrypsin (AAT), the protein encoded by SERPINA1, remains the strongest genetic risk factor for COPD. Individuals heterozygote for the type Z variant, termed the PI*MZ genotype (estimated global prevalence n = 35,000,000), experience varying respiratory morbidity beyond expected from tobacco smoking alone. AAT is a pleiotropic protein which inhibits not only neutrophil elastase but also neutrophil chemotaxis mediated by leukotriene B4 (LTB4) [by antagonizing the LTB4 receptor (LTB4R)] and interleukin-8 (IL-8). Although LTB-4 and IL-8 gene variants and protein levels have independently been implicated in COPD, their potential role in PI*MZ is unknown. Methods COPDGene and SPIROMICS are observational tobacco-smoke and COPD-enriched cohort studies. Participants were phenotyped by spirometry and CT imaging, with whole genome sequencing data available via TOPMed. We analyzed participants with PI*MM (COPDGene n = 9,732; SPIROMICS n = 2,105) and PI*MZ (COPDGene n = 300; SPIROMICS n = 83). LTB-4 (ALOX5AP, LTA4H, LTB4R) and IL-8 (CXCL8, CXCR1, CXCR2) associated gene variants (exonic and intronic) with a minor allele frequency of ≥ 0.05 were extracted. We assessed statistical interactions between MZ status and chest CT outcomes or FEV1% predicted using the SPAGxECCT package with adjustment for relatedness (genetic related matrix) and ancestry (top ten PCs). Baseline protein LTB4R (SPIROMICS only) and IL-8 (both cohorts) protein levels were measured via SomaScan, and statistical interactions between MZ status and AAT concentration were explored. Models were adjusted for age, sex, BMI, smoking status, and pack-years. Given the candidate gene discovery approach, significance was defined as nominal p-value<0.05 Results We identified the following number of variants in genes of the LTB-4 or IL-8 pathways: 87 shared between cohorts; 133 unique to COPDGene; 1 unique to SPIROMICS. LTB-4-related polymorphisms were associated (p < 0.05) with any radiographic outcomes in 22 variants (COPDGene) vs. 23 variants (SPIROMICS), with a single overlap (rs17074984 in ALOX5AP). Two LTB-4-pathway variants were associated with FEV1% predicted in SPIROMICS (both in ALOX5AP), but none in COPDGene. AAT plasma concentrations displayed a statistically significant interaction with FEV1% predicted (p = 0.046) and PRMemphysema (p = 0.013) for LTBR4, but not for IL-8. There was not an interaction by MM/MZ status and protein levels. Conclusions Predominantly LTB-4, and not IL-8, pathway-related genetic variants and protein levels may contribute to disease heterogeneity among PI*MZ individuals. The association of circulating LTB4R protein with reduced lung function, particularly among those with low AAT levels, further suggest interactions between AAT and the leukotriene pathway in PI*MZ individuals. Thus, PI*MZ individuals may uniquely derive benefit from leukotriene-targeting pharmacotherapy. This abstract is funded by: NIH NHLBI K23HL173570
Metabolomics of Right Ventricular Function in Pulmonary Hypertension
Chacon-Barahona, Jonathan , Chung, Samuel J. , Garry, Jonah , Frantz, Robert P. , Hassoun, Paul M. , Mathai, Stephen C. , Simpson, Catherine E. , Beck, Gerald, Hill, Nicholas S. , MUKHERJEE, MONICA, Jacob, Miriam , Park, M H, Finet, J Emanuel, Farha, Samar , Grünig, Gabriele , Kwon, Deborah, Comhair, Suzy , Erzurum, Serpil, Barnard, John, Jellis, Christine , Racanelli, Alexandra Christin, Krumsiek, Jan , hemnes, anna, Horn, Evelyn, Group, on behalf of the PVDOMICS Study, Beck, Gerald J. , Garry, Jonah D , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Beck, Gerald J , Hill, Nicholas S , Leopold, Jane A , Waxman, Aaron B. , Rosenzweig, Erika B , Borlaug, Barry A , Mukherjee, Monica , Vanderpool, Rebecca R , Jacob, Miriam , Mehra, Reena , Park, Margaret M , Finet, J Emanuel , Kwon, Deborah H , Comhair, Suzy , Erzurum, Serpil C , Barnard, John , Hu, Bo , Jellis, Christine L , Krumsiek, Jan , Brittain, Evan L , Hemnes, Anna , Horn, Evelyn M , Frantz, Robert P , Chacon-Barahona, Jonathan , Chung, Samuel J. , Rischard, Franz , Leopold, Jane A. , Rosenzweig, Erika B. , Borlaug, Barry A. , Mukherjee, Monica , Vanderpool, Rebecca , Mehra, Reena , Finet, J. Emanuel , Erzurum, Serpil C. , Racanelli, Alexandra C. , Hemnes, Anna R. , Gro, on behalf of the PVDOMICS Study

Mayo Clinic

Circulation Research | April 15, 2026 | Volume: 138 | Issue: 11 | Pages: No page available

10.1161/circresaha.125.327342 | PMID 41983297 Get It

BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.
Deep learning-derived measures of sound-level accuracy in primary progressive apraxia of speech: A feasibility pipeline with descriptive evidence from two cases
Wang, Fenqi , Duffy, Joseph R., Bachman, Ashley D. , Barnard, Leland R , Botha, Hugo , Utianski, Rene L., Duffy, Joseph R. , Utianski, Rene L. , Duffy, Joseph R , Utianski, Rene L , Botha, Hugo , Barnard, Leland , Wang, Fenqi

Mayo Clinic

Clinical Linguistics & Phonetics | March 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-19

10.1080/02699206.2026.2639397 | PMID 41800702 Get It

Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension
Reddy, Yogesh N.V., Frantz, R, Miranda, William R., Asokan, Aneesh K , Varma, Revati, Rischard, Franz , Hassoun, Paul M., Hemnes, Anna R. , Horn, E., Leopold, Jane A. , Rosenzweig, Erika B., Hill, N.S., Erzurum, Serpil C., Beck, Gerald J. , Barnard, John, Finet, J. Emanuel , Kwon, Deborah , Mathai, Stephen C., MUKHERJEE, MONICA, Borlaug, Barry A., Frantz, Robert P. , Horn, Evelyn M. , Hassoun, Paul M. , Mathai, Stephen C. , Reddy, Yogesh N.V. , Nishimura, Rick , Frantz, Robert P , Miranda, William R , Hassoun, Paul M , Horn, Evelyn M , Rosenzweig, Erika B , Hill, Nicholas S , Erzurum, Serpil C , Barnard, John , Mathai, Stephen C , Mukherjee, Monica , Tang, W H Wilson , Borlaug, Barry A , Hemnes, Anna , Rischard, Franz P , Leopold, Jane A , Miranda, William R. , Varma, Revati , Erzurum, Serpil C. , Mukherjee, Monica , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

Circulation | February 13, 2026 | Volume: 153 | Issue: 13 | Pages: 948-962

10.1161/circulationaha.125.077606 | PMID 41685452 Get It

BACKGROUND: With pulmonary hypertension (PH), a pulmonary artery wedge pressure (PAWP)>15 mm Hg is used to diagnose left heart dysfunction, but some patients with adjudicated group 1 PH demonstrate PAWP>15 mm Hg. The primary objective of the study was to evaluate group 1 PH with high PAWP>15 mm Hg. METHODS: Patients with adjudicated group 1 PH from PVDOMICS between 2016 and 2019 were separated into high PAWP(>15 mm Hg) or normal PAWP and compared with adjudicated combined pre- and postcapillary (Cpc) PH related to heart failure with preserved ejection fraction (HFpEF). Participants underwent dynamic right heart catheterization and metabolomics. Findings were validated in 3 independent cohorts with adjudicated group 1 PH (validation cohorts 1 and 2 with exercise right heart catheterization and validation cohort 3 with resting right heart catheterization). RESULTS: Of 325 patients with group 1 PH (73% women, mean age 53.0±14.3 years), 15% (n=48) had high PAWP. Group 1 PH+high PAWP demonstrated greater obesity, left ventricular hypertrophy ( P <0.0002), left ventricular strain impairment ( P <0.0001), and decreased left ventricular compliance ( P <0.0001) compared with group 1 PH+normal PAWP, with changes comparable to Cpc-PH HFpEF (n=75). Compared with Cpc-PH HFpEF, left atrial function was better in group 1 PH+high PAWP with lower PAWP V wave, higher left atrial compliance, and left atrial ejection fraction ( P <0.0001 for all). Metabolomics demonstrated little difference between group 1 PH with high versus normal PAWP but large differences between group 1 PH+high PAWP versus Cpc-PH HFpEF (100 metabolites altered at false discovery rate P <0.05). Elevated PAWP was also observed in 18% of group 1 PH in the validation cohort 1 (n=402), with exercise PAWP response intermediately abnormal in group 1 PH+high PAWP relative to Cpc-PH HFpEF and group 1 PH+normal PAWP (interaction P <0.0001). Elevated PAWP was similarly observed in 22% and 19% of group 1 PH in validation cohorts 2 (n=55) and 3 (n=787), respectively. CONCLUSIONS: Approximately 1 in 5 adjudicated patients with group 1 PH has elevation in resting PAWP despite severe pulmonary vascular dysfunction and metabolomics consistent with traditionally defined group 1 PH. Despite resting PAWP elevation, these patients with group 1 PH were metabolomically and biologically distinct from Cpc PH HFpEF, with better left atrial function and diastolic reserve during exercise. These data emphasize the limitations of using resting PAWP alone to separate group 1 PH from HFpEF and call for development of more integrated clinical diagnostic criteria.
Skin Biopsy for Phosphorylated α‐Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice
Botha, Hugo, Barnard, Leland R , Reichard, R. Ross, Larsen, Rachel A. , Cogan, Wendy, Switzer, Aaron , Ramanan, Vijay K., Neth, Bryan J. , Townley, Ryan , Savica, Rodolfo , Jones, D., Miyagawa, Toji , Fields, Julie A. , Vernon, Cynthia J. , Trottier, Zachary A., Lowe, Val J. , Knopman, David S., Petersen, Ronald C., Dickson, Dennis W., Kantarci, Kejal, Graff‐Radford, Jonathan, Boeve, B. F., Kantarci, Kejal , Rigby, Michael J. , Larsen, Rachel, Savica, Rodolfo , Miyagawa, Toji , St Louis, E K , Kantarci, Kejal , Graff-Radford, Jonathan , McCarter, Stuart J , Neth, Byran J. , Switzer, Aaron R , Botha, Hugo , Reichard, R. Ross , Ramanan, Vijay K. , Jones, David T. , Vernon, Cynthia, Trottier, Zachary, Louis, Erik K. St. , Knopman, David S. , Petersen, Ronald C. , Graff‐Radford, Jonathan , McCarter, Stuart J.

Mayo Clinic

Movement Disorders | December 29, 2025 | Volume: 41 | Issue: 4 | Pages: 962-971

10.1002/mds.70158 | PMID 41459992 Get It

Abstract Background Immunohistochemically detected phosphorylated α‐synuclein (p‐α‐syn) in cutaneous nerves has been found in >95% of patients meeting consensus criteria for dementia with Lewy bodies (DLB); however, its performance in prodromal stages (mild cognitive impairment‐Lewy body [MCI‐LB]) and clinical practice is unknown. Objective We evaluated skin biopsy for p‐α‐syn in a convenience cohort of patients with suspected MCI‐LB or DLB in a tertiary care setting. Methods 53 patients underwent commercially available skin biopsy for skin nerve p‐α‐syn as part of a clinical evaluation for suspected MCI‐LB/DLB. Consensus MCI‐LB/DLB criteria blinded to skin biopsy result were applied through retrospective chart review; those not definitively meeting criteria were considered questionable synucleinopathy (QS). Results Median age at skin biopsy was 70 years (range, 43–87 years) with 81% men. 36 patients (68%) had positive skin biopsies. 32/43 (74%) patients meeting clinical consensus criteria for DLB/MCI‐LB had a positive skin biopsy, with higher frequency in MCI‐LB (87%) compared with DLB (60%). 4/10 (40%) QS had positive biopsies. One patient with a positive skin biopsy had no evidence of central nervous system (CNS) α‐syn on autopsy. Conclusions Positive skin biopsy for p‐α‐syn occurs across the spectrum of cognitive presentations of Lewy body disease including prodromal DLB, albeit at a lower frequency in this retrospective review of atypical cases compared with typical clinical presentations. A positive skin biopsy may not reflect CNS synucleinopathy as the etiology for a patient's symptoms in some cases. Longitudinal studies of skin biopsies for p‐α‐syn in suspected MCI‐LB/DLB with autopsy confirmation are needed. © 2025 International Parkinson and Movement Disorder Society.
An Evaluation of the Remotely Administered MASTERMIND Assessment of Naming
Utianski, Rene L, Duffy, J, Barnard, Leland, Stricker, John L. , Petersen, R. C., Jones, David T., Botha, Hugo, Utianski, Rene L. , Duffy, Joseph R. , Barnard, Leland R , Petersen, Ronald, Jones, David T. , Botha, Hugo

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_100512 Get It

Abstract Background To promote equitable access to neurologic diagnostics, our team developed MASTERMIND—the Mobile Assessment of Speech To Evaluate, Recognize, and Monitor Indicators of Neurologic health and Disease. One subtest, the MASTERMIND Assessment of Naming, includes ten pictures randomly selected from a list of 45 words varying in frequency. This study aimed to 1) evaluate the feasibility of a remotely self‐administered naming test for patients with cognitive, linguistic, and/or communication difficulties and 2) assess the sensitivity and specificity of performance measures (accuracy, error type, and response time) for detecting aphasia and cognitive‐communication difficulties. Method The task was remotely administered to 138 controls, 26 cognitively impaired individuals, 15 with motor speech disorders, 8 with cognitive concerns, and 6 with aphasia. Participants named pictures displayed on‐screen, advancing through the task by clicking “Next.” Responses were processed using natural language processing (NLP). Audio was transcribed with Whisper Large‐v3, and responses were matched to stimuli within a 0.4‐second threshold. Errors were categorized by type (semantic, phonemic, or unclear source) through consensus between two raters. Performance metrics (accuracy, error type, response time) were analyzed using Kruskal‐Wallis and Pearson's Chi‐Square tests, with AUROC analysis evaluating diagnostic performance. Results Differences in accuracy, response time, and error type were observed across groups (Table 1). Controls and cognitively impaired participants performed similarly, with longer response times observed in patients with aphasia and motor speech disorders. Accuracy alone was a poor predictor of all patients versus controls (AUROC = 0.468) but prediction was better in distinguishing aphasia patients from 1) controls (AUROC = 0.698), 2) cognitively impaired participants (AUROC = 0.679), and 3) those with MSDs (AUROC = 0.670). Conclusions The MASTERMIND Assessment of Naming is a feasible, scalable, self‐administered diagnostic tool enhanced by automated NLP. It provides critical insights through response time, accuracy, and error analysis. Limitations include potential bias in error classification and fixed processing thresholds. The study highlights MASTERMIND's potential for patient triaging and screening. Future research will evaluate the sensitivity of combined performance metrics to disease progression, expand sample sizes and diversity, and refine usability based on participant feedback.
Prediction of neuropathology using the FDG‐PET based patient similarity network
Zhang, Gemeng , Barnard, Leland, Botha, Hugo, Gogineni, Venkatsampath, Graff‐Radford, Jonathan, Huls, Sean J. , Stricker, John L. , Fan, Winnie Z. , Wiste, Heather J. , Machulda, Mary M., Murray, Melissa E., Reichard, R. Ross, Gunter, Jeffrey L. , Schwarz, Christopher G, Kantarci, Kejal, Whitwell, Jennifer L., Josephs, K., Knopman, David S., Boeve, Brad F, Petersen, Ronald, Jack, Clifford R., Lowe, Val J. , Jones, David T., Barnard, Leland R , Botha, Hugo , Corriveau‐Lecavalier, Nick , Graff‐Radford, Jonathan , Burkett, Brian J. , Johnson, Derek R. , Khurana, Aditya , Min, Hoon-Ki Paul , Senjem, Matthew L. , Machulda, Mary M. , Murray, Melissa E. , Dickson, Dennis W. , Nguyen, Aivi T. , Reichard, R. Ross , Schwarz, Christopher G. , Kantarci, Kejal , Whitwell, Jennifer L. , Knopman, David S. , Petersen, Ronald, Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_103746 Get It

Abstract Background Neuropathologic evaluation is essential for diagnosing and treating dementia, but definitive diagnoses is only available after post‐mortem brain autopsy. Positron emission tomography (PET) offers a potential in vivo proxy for predicting neuropathology. This study proposes a semi‐supervised learning (SSL) model using a single FDG‐PET image to predict underlying neuropathology. Method The SSL model leverages a self‐organized graph structure based on a patient similarity network (PSN) created from 1,495 FDG‐PET images across the aging and neurodegenerative spectrum. Each patient is represented by a node, with edges indicating image similarity derived from principal component analysis features and cosine similarity weights. The PSN structure connects 20 nearest neighbors. Neuropathologic labels were available for 204 autopsied patients. The Poisson Learning Method was employed to propagate labels from these annotated nodes to unlabeled nodes, guided by the PSN structure. FDG‐PET images were collected from clinical and research participants at the Mayo Clinic and processed using an MRI‐free pipeline. Neuropathologic labels were assigned based on widely accepted diagnostic criteria. Leave‐one‐out cross‐validation (LOOCV) was used to assess model performance. Results The confusion matrix demonstrated high accuracy in predicting Alzheimer's disease, frontotemporal lobar degeneration with tau inclusions, and Lewy body disease pathology. A Sankey diagram and label distribution analysis revealed strong correlations between clinical and predicted neuropathologic labels. Conclusion This study highlights the potential of a graph‐based SSL pipeline to predict neuropathological changes using FDG‐PET imaging data, despite limited pathology labels. The findings underscore the value of SSL in bridging the gap between abundant neuroimaging data and scarce neuropathologic labels, contributing to improved dementia diagnosis and understanding.
Gait Analysis in Neurologic Disorders
Ali, Farwa , Padilla, Hannah, Blazek, Audrey M. , Barnard, Leland R , Barnard, Leland , Kaufman, Kenton R.

Mayo Clinic

Neurology | September 19, 2025 | Volume: 105 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000214154 | PMID 40971743 Get It